Adrenal Cancer Survival Rates: How Common Adrenocortical Carcinoma Is and What the Numbers Mean

Most people arrive at a page about adrenal cancer survival rates frightened, and often within a day or two of hearing the diagnosis. This guide is written with that in mind. It gives you the real numbers, explains carefully what they can and cannot tell you, and points out the parts of your situation that actually change the outlook.

Two things are worth saying before any statistics appear. First, adrenocortical carcinoma (ACC), the cancer of the outer layer of the adrenal gland, is genuinely serious, and we are not going to soften that. Second, the averages you will read include people at every stage, treated at every kind of hospital, over many years, and a great many of them do not describe your situation. Some people with ACC are cured.

A note on scope, because "adrenal cancer" covers more than one disease. This guide is about ACC unless it says otherwise. Pheochromocytoma and paraganglioma (PPGL) start in the adrenal medulla, the inner core of the gland, and they have a different and generally better outlook. We cover that separately and clearly below. And adrenal metastases, meaning a cancer that started somewhere else such as the lung or breast and later spread to an adrenal gland, are not adrenal cancer at all. They carry the outlook of the original cancer and are treated as that cancer.

How Common Is Adrenal Cancer?

Adrenocortical carcinoma is one of the rarest cancers there is. Published reviews put the worldwide incidence at 0.5 to 2.0 cases per million people per year. That works out to roughly 300 to 400 new cases each year in the United States. The American Cancer Society takes a more cautious line and says the exact number diagnosed in the United States each year is not known, and is probably around 200 per year. A Finnish national study gives a useful real-world check on those figures: the age-standardised incidence there was 0.9 per million person-years for 2006 to 2010 and 1.0 per million person-years for 2011 to 2015. However you count it, ACC accounts for well under 1% of all cancers, which is why most oncologists will treat only a handful of cases in an entire career.

Why do the numbers you find online disagree with each other? The National Cancer Institute's SEER program publishes a widely used series called Cancer Stat Facts, with a summary page for each cancer type. There is no Cancer Stat Facts page for adrenal cancer. The A to Z list of single cancer sites simply does not include an adrenal entry, because Cancer Stat Facts covers "a number of common cancer types" and ACC is not one of them. So the figures in this guide come from the American Cancer Society, from SEER Explorer queries, from national and hospital registry analyses, and from published case series. Those sources use different definitions, different time periods, and different populations, and they do not always agree. If you see one site say 40% and another say 80%, neither is necessarily lying. Being upfront about that variation matters more here than in almost any other cancer.

ACC has an unusual age pattern with two peaks rather than one. The first peak is in children younger than 5 years. The second and larger peak is in adults in the fourth to fifth decades of life, meaning roughly the thirties through the fifties. Children make up about 5% to 10% of all ACC diagnoses, and most childhood cases appear before age 15. If you are a parent reading this for your child, that pattern is real, and it is not a mistake in the data. Pediatric ACC behaves differently from adult ACC; it is treated by a pediatric oncology team, and its outlook is often better than the adult averages suggest. We come back to that below.

Adrenal cancer affects women and men, and among adults it is somewhat more common in women. Reported female-to-male ratios run from about 2.5 to 1 up to 3 to 1, and the female predominance is more pronounced in younger adults. There are also geographic differences that look dramatic on a map. In southern Brazil, childhood ACC is far more common than anywhere else in the world, with reported rates of 10 to 15 cases per million children. The reason is genetic rather than environmental. A specific inherited change in the TP53 gene, called p.R337H, is unusually common in the general population of that region because of a founder effect, meaning it traces back to a shared ancestor and has been passed down widely. Newborn screening programs there have used this knowledge to find tumors very early, and early detection in that setting has produced far better outcomes than late detection.

One more distinction, and it is the one readers most often get wrong. Adrenal masses are common. Adrenal cancer is not. The American Cancer Society reports that adrenal tumors are found in about 1 in every 10 people who have a CT or MRI of the adrenal gland, and most of those are benign adenomas, meaning harmless growths that will never spread. A mass found by accident on a scan done for something else is called an incidentaloma, and it is a finding, not a diagnosis. If you are reading this because a scan picked up a spot on your adrenal gland, the odds are strongly in your favor, and the survival numbers below almost certainly do not apply to you. What applies to you is finishing the hormone testing and imaging your doctor ordered. Our guides on how adrenal cancer is diagnosed and adrenal cancer facts walk through that workup.

Two other features of ACC help explain the survival figures that follow. ACC tumors are usually large by the time they are found, averaging about 10 to 13 cm across, which is roughly the size of a grapefruit. And about 40% to 60% of ACC tumors are functional, meaning they pour out extra adrenal hormones. Tumors that make no hormones announce themselves later and tend to be even larger at diagnosis, because nothing tips anyone off early. Neither of those facts is anyone's failure to notice. The adrenal glands sit deep in the back of the belly where a tumor has room to grow quietly.

What Is the Survival Rate for Adrenal Cancer?

Before any number, please read this paragraph, because the statistics for this cancer are genuinely sobering, and they are also more limited than they look. A five-year relative survival rate compares people who have a particular cancer with people in the general population who do not have it. The American Cancer Society explains it this way: if the five-year relative survival rate for a specific stage of adrenal cancer is 80%, it means that people who have that cancer are, on average, about 80% as likely as people who do not have that cancer to live for at least five years after being diagnosed. It is not a prediction. It does not mean you have five years. It does not mean 20% of people die at exactly five years. It is a group average, looking backward, over a large mixed population.

Now the figures. The American Cancer Society, drawing on SEER data for people diagnosed with cancers of the adrenal gland between 2015 and 2021, reports five-year relative survival of 80% for localized disease, meaning no sign the cancer has spread outside the adrenal gland, 62% for regional disease, meaning spread to nearby structures or lymph nodes (small glands that help fight infection), and 39% for distant disease, meaning spread to places such as the liver or lungs. All stages combined come to 57%. Two important caveats travel with those numbers. SEER does not group adrenal cancers by AJCC or ENSAT stage, so these are broad localized, regional, and distant categories rather than stage I through stage IV. And the SEER category is "cancers of the adrenal gland" as a group, which is broader than ACC alone, so these figures are more favorable than ACC-specific series tend to be.

For ACC specifically, the numbers most often quoted come from series that use ENSAT staging, the system developed by the European Network for the Study of Adrenal Tumors. Pooling published series, five-year overall survival runs about:

• Stage I - 66% to 82%

• Stage II - 58% to 64%

• Stage III - 4% to 50%

• Stage IV - 0% to 17%

Notice how wide those ranges are. That width is not sloppiness. It reflects real differences between hospitals, eras, and patient populations, and it is one of the clearest signals in the whole dataset that where and how you are treated matters. Our guide to adrenal cancer stages explains what each stage actually means.

Four things that drive the outcome:

• Stage at diagnosis

• Complete surgical removal is the most important prognostic factor of all: an R0 resection, meaning the whole tumor is taken out with clean margins and no cancer left behind, produces substantially better outcomes than an R1 resection (microscopic cancer at the edge) or an R2 resection (visible cancer left behind).

• Ki-67 proliferation index, a laboratory measure of what share of tumor cells are actively dividing; a Ki-67 above 20% is linked with worse outcomes.

• Tumor grade, meaning how abnormal the cells look under the microscope.

Molecular features such as a TP53 mutation in the tumor also carry prognostic weight. The National Cancer Institute lists the same short list of factors that shape prognosis: the stage, whether the tumor can be completely removed by surgery, whether the cancer has been treated before, your general health, and the grade of the tumor cells.

Now the limits of these numbers, all of which cut in your favor. They describe people diagnosed years ago, treated with what was available then, so they cannot reflect newer surgical techniques, better hormone control, or newer systemic therapy. They are relative survival figures, so they include people who died of heart disease, accidents, and everything else unrelated to their cancer. They lump together everyone in a stage, and survival within a single stage varies enormously depending on Ki-67, on grade, on hormone control, and above all on whether the tumor came out completely. And they say nothing about any one person. To see how much variation is possible, consider a contemporary Finnish series in which five-year survival for ENSAT stage I to III patients reached 96%, which the authors themselves noted compares favorably with previous studies. That is one small series, and it is not a promise, but it shows that the older grim averages are not a ceiling.

Two groups do considerably better than the overall averages suggest, and both are worth naming plainly. People with early-stage disease that was completely removed do much better, and the National Cancer Institute states directly that adrenocortical carcinoma may be cured if treated at an early stage. And children with ACC often do well: the National Cancer Institute says the prognosis is good for patients who have small tumors that have been completely removed by surgery. Being honest about ACC means saying both halves out loud. Widely spread disease has a hard outlook. Localized, completely resected disease frequently does not.

Pheochromocytoma and Paraganglioma Have a Different and Generally Better Outlook

Pheochromocytoma is a different adrenal cancer, and it works differently, so please do not apply the numbers above to it. PPGL starts in the adrenal medulla or in nerve tissue outside the gland, causes surges of adrenaline and noradrenaline rather than steroid hormone excess, is diagnosed with metanephrine testing and MIBG or DOTATATE type scans, and is driven by a different set of genes including SDHB, SDHD, VHL, RET, and NF1. Most pheochromocytomas are removed and never come back, though because any of them can eventually spread, long-term follow-up is standard rather than a single all-clear.

Even when PPGL does spread, the picture differs from metastatic ACC. Metastatic PPGL is rarer still, at less than one case per million people per year. A large European study from the ENSAT network, called MAPP-Prono, followed 169 patients with metastatic pheochromocytoma or paraganglioma and reported a median survival of 6.7 years, with published five-year survival in the literature ranging from 40% to 77%. The same group had previously shown that about half of patients with metastatic PPGL have stable disease at one year without any treatment at all, which is a pattern you almost never see in metastatic ACC. Better survival in that study was associated with head and neck paraganglioma, age under 40, metanephrine levels less than five times the upper limit of normal, and a low proliferative index. If PPGL is your diagnosis, the ACC survival figures in this guide are the wrong numbers for you, and you should ask your team for PPGL-specific information.

Is Adrenal Cancer Curable?

Yes, for some people. The National Cancer Institute states plainly that adrenocortical carcinoma may be cured if treated at an early stage, and complete surgical removal is described in the clinical literature as the only potentially curative treatment for this disease. In practice, that means people with stage I and stage II ACC whose tumor is taken out completely, with clean margins, by a surgeon experienced in adrenal cancer, have a real chance at cure. Expected mortality from the operation itself is under 5%, though that varies with surgical expertise and with how sick a person is going in. Our guide to adrenal cancer treatment explains what that surgery involves.

It helps to sort out three words that get used interchangeably and mean different things. Remission means the signs of cancer have decreased or disappeared. No evidence of disease, often shortened to NED, means that scans, blood work, and examination find nothing, which is not quite the same as a guarantee that nothing is there. Cure means the cancer is gone and will not return, and with ACC that is a judgment made only in hindsight, after years of clean follow-up. Many people with ACC live in NED for a long time before anyone is willing to use the word cure, and that gap is uncomfortable. Naming the difference sometimes makes the waiting easier to sit with, because it stops you from hearing "no evidence of disease" as either a brush-off or a promise.

This is why follow-up is not optional. Local recurrence, meaning the cancer coming back in or near where it started, happens in about 19% to 34% of completely resected cases, and distant metastases develop in more than half of people with ACC at some point. Standard surveillance after surgery is a visit with imaging and hormone tests every 3 months for the first 2 years, then every 6 months until year 5, and once a year after that. If that schedule feels relentless, that is because recurrence risk is real and because catching a recurrence early is what keeps further curative treatment on the table. Missing appointments is the one avoidable way to lose that option.

Recurrent and limited spread disease is sometimes still treated with the intention to cure, which surprises many people. Repeat surgery is recommended for an R2 resection when it is technically feasible, meaning if visible tumor was left behind, going back in is often the right move rather than a lost cause. Removing metastases, called metastasectomy, can provide a survival benefit for people with oligometastatic disease, meaning a small number of spots in a small number of places, particularly when complete removal is achievable. Multiple groups have shown this benefit, most often for lesions in the liver, lung, and bone, and it depends on careful patient selection and surgical expertise. So a scan showing one or two new spots is a reason to ask about aggressive local treatment, not a reason to assume the goal has changed.

Widely metastatic ACC is generally not curable, and that sentence deserves to stand without decoration. It is, however, very much treatable. Standard systemic therapy exists, clinical trials exist, radiation to painful or troublesome sites exists, and debulking surgery has a defined role for people with disease limited to two or fewer organs, a resectable tumor mass, slow progression, or severe hormone excess that cannot be managed with medicine alone. Treatable is not the same as curable, and it is also not the same as nothing to be done. The distance between those two is where most of modern ACC care lives.

Controlling hormone excess deserves its own emphasis, because it changes how a person actually feels even when the cancer itself cannot be cured. The combination of tumor burden and hormone excess occurs in nearly half of people with ACC. Uncontrolled high cortisol causes hard-to-control diabetes, deep muscle weakness, severe bone thinning with fractures, psychiatric effects including serious depression, and dangerous blood pressure and potassium problems. High cortisol is also an adverse prognostic factor in its own right, which is why every effort is made to bring hormone levels down: it affects both survival and quality of life. If you are exhausted, weak, low in mood, and gaining weight in a pattern you do not recognize, that is not something to endure quietly while everyone focuses on the tumor. It is treatable, and treating it is part of treating the cancer.

Three actions carry more weight than anything else, and all three are things you can start this week. Ask for referral to a high-volume adrenal center before the first operation, not after, because complete removal by an experienced surgeon is the strongest factor you can still influence, and there is only one first chance at it. Ask for genetic counseling, because hereditary syndromes cause a meaningful share of ACC, especially in children, and current guidelines recommend offering counseling and testing to everyone diagnosed with ACC regardless of age or family history; what it finds can change your own follow-up and protect your relatives. And ask about joining a clinical trial for adrenal cancer, because in a disease this rare, trials are a normal part of good care rather than a last resort. Everything in this guide is general information about groups of people. For what these numbers mean in your case, ask your own care team, who know your stage, your pathology, and your surgery, and who are the only people who can put your name next to any of it. Our guide to questions to ask about adrenal cancer is built for exactly that conversation, and if the emotional weight of these numbers is heavy right now, our adrenal cancer support guide lists people who can help carry it.

Sources:

• Survival Rates for Adrenal Cancer, American Cancer Society

• Key Statistics for Adrenal Cancer, American Cancer Society

• Childhood Adrenocortical Carcinoma, National Cancer Institute

• Cancer Stat Facts, National Cancer Institute Surveillance, Epidemiology, and End Results Program

• SEER Explorer, National Cancer Institute Surveillance, Epidemiology, and End Results Program